What happened with FULC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Fulcrum Therapeutics is a clinical-stage drug developer focused on rare diseases, chiefly blood disorders. Its only candidate in active clinical development is pociredir for sickle cell disease. The drug is designed to increase fetal hemoglobin production by changing how cells regulate gene activity.
Fulcrum has no approved products and has not generated product-sale revenue. It has funded operations mainly through sales of stock and upfront collaboration and licensing payments. Sanofi previously paid for rights to sell losmapimod outside the United States, but that agreement ended after the drug failed its main late-stage trial goal and Fulcrum suspended development.
Fulcrum plans to retain pociredir’s rights and build a focused sales operation for an approved treatment, while potentially using partners for some candidates or markets outside the United States. It relies on outside manufacturers for drug supplies. Its path to product revenue depends heavily on pociredir succeeding in trials, receiving regulatory approval and securing insurance coverage and reimbursement; continued development also requires additional financing.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Fulcrum's prospects hinge on pociredir's clinical success and how it stands apart from other sickle cell treatments, including privately held Cellarity's CLY-124.
Agios Pharmaceuticals competes with Fulcrum's oral rare-blood-disease ambitions: it develops mitapivat and tebapivat for sickle cell disease and already sells mitapivat for thalassemia. Watch its sickle cell trial results for the competition pociredir would face, while Fulcrum still has no product sales.
Beam Therapeutics' investigational BEAM-101 competes with Fulcrum's pociredir for treating sickle cell disease; neither company has product-sale revenue. Beam develops medicines that change individual DNA letters, so watch BEAM-101's efficacy and safety results as a comparison for pociredir.
CRISPR Therapeutics already has an approved treatment, CASGEVY, in diseases Fulcrum hopes to address with pociredir. Its approval in the United States and other countries for eligible patients with severe sickle cell disease or transfusion-dependent beta thalassemia sets an existing treatment benchmark for Fulcrum's still-investigational drug.
Vertex Pharmaceuticals sells CASGEVY to treat sickle cell patients whom Fulcrum hopes to reach with pociredir. Watch CASGEVY sales through distributors and, in some markets, directly to authorized treatment centers for evidence of the competition already reaching those patients.
Editas Medicine is developing medicines that edit cells inside the body for patient groups Fulcrum seeks to treat with pociredir. Watch progress in its sickle cell disease and transfusion-dependent beta thalassemia programs for potential competition to Fulcrum's small-molecule approach.
Fulcrum Therapeutics, Inc. earningsThis company
Fulcrum Therapeutics has no product-sale revenue, so its report will show whether its cash can keep funding development of its sickle cell candidate pociredir.
Read cash used in operations and the cash, cash-equivalents and marketable-securities balance alongside research spending on pociredir. Contained cash use with continued investment in the candidate would support advancing the program as planned; faster cash use or reduced investment would mean less time and more pressure to raise funds.
Vertex Pharmaceuticals Inc earningsVRTX
Vertex's report will show whether patients are taking up its approved sickle cell treatment CASGEVY, in the patient group Fulcrum Therapeutics hopes to reach.
Look at CASGEVY sales and what Vertex says about getting the treatment to patients. Growing sales would show that an existing therapy is reaching more patients, giving pociredir a more established treatment to compete with if approved; limited sales would show uptake is constrained, but would not prove patients would choose unapproved pociredir.
Agios Pharmaceuticals, Inc. earningsAGIO
Agios Pharmaceuticals' report will show how its sickle cell candidates are progressing, offering a competition benchmark for Fulcrum Therapeutics' oral candidate pociredir.
Read Agios's sickle cell trial efficacy and safety updates against the fact that pociredir is also still in clinical development. Convincing efficacy with acceptable safety would strengthen the evidence for a competing oral treatment approach; limited results or safety concerns would weaken that case.
